New lupus drug candidate BMS-986326 enters early human testing

NCT ID NCT06013995

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new drug called BMS-986326 in 45 adults with different forms of lupus, including skin and systemic lupus. The main goal was to check safety and how the body processes the drug, not yet to see if it works. Participants received either the drug or a placebo through an IV or injection, and researchers monitored side effects and drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BMS-986326
What this could lead to: If this drug is safe and shows promise, it could point toward a new treatment option for lupus that helps control the disease.
What could go wrong: This is a very early, small phase 1 trial focused on safety, not effectiveness. The drug may not work or could have side effects. Many early-stage drugs fail to advance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous lupus erythematosus discoid lupus erythematosus lupus erythematosus subacute cutaneous lupus erythematosus systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS

Contacts and locations

Show contact details

Locations

Arthritis Northwest, PLLC

Spokane, Washington, 99204, United States
Local Institution - 0005

Duncansville, Pennsylvania, 16635, United States
Local Institution - 0029

Tampa, Florida, 33606, United States
Local Institution - 0044

Berlin, 10117, Germany
Local Institution - 0045

Córdoba, Córdoba, 14004, Spain
Local Institution - 0046

A Coruña, A Coruña [La Coruña], 15006, Spain
Local Institution - 0047

Dresden, 01307, Germany
Local Institution - 0048

San Diego, California, 92108, United States
Local Institution - 0051

Leiden, 2333 CL, Netherlands
Local Institution - 0055

Clearwater, Florida, 33765, United States
Local Institution - 0062

Las Vegas, Nevada, 89102, United States
Local Institution - 0064

Cluj-Napoca, Cluj, 400006, Romania
Local Institution - 0065

Bucharest, Bucharest, 11658, Romania
Local Institution - 0069

Warsaw, 02-953, Poland
Local Institution - 0070

Pilar, Buenos Aires, 1629, Argentina
Local Institution - 0071

Dessau, 06847, Germany
Local Institution - 0072

Sofia, 1618, Bulgaria
Local Institution - 0074

Poznan, 61-848, Poland
Local Institution - 0075

CABA, Buenos Aires F.D., 1430, Argentina
Skin Sciences

Louisville, Kentucky, 40217, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.